Arbutus Biopharma Corporation (ABUS)

Market Cap	323.38M
Revenue (ttm)	23.54M
Net Income (ttm)	-72.93M
Shares Out	167.56M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,127,650
Open	1.97
Previous Close	1.99
Day's Range	1.88 - 1.97
52-Week Range	1.85 - 3.15
Beta	2.13
Analysts	Strong Buy
Price Target	6.00 (+210.88%)
Earnings Date	Nov 8, 2023

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: William H. Collier
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: ABUS

Financial Performance

In 2022, ABUS's revenue was $39.02 million, an increase of 255.11% compared to the previous year's $10.99 million. Losses were -$69.46 million, -21.42% less than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for ABUS stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 210.88% from the latest price.

Price Target

$6.0

(210.88% upside)

Analyst Consensus: Strong Buy